we used a temporary price dislocation caused by disappointing clinical trial results to purchase shares of Novo Nordisk A/S (NYSE:NVO), a Danish-based leader in diabetes and obesity treatments.

The two deals are firmly within Novo Nordisk’s cardiometabolic focus – driven by semaglutide drugs Ozempic for diabetes and Wegovy for obesity – and include an Omega mRNA drug for obesity ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the ... the same active ingredient as its popular obesity treatment, Wegovy. With the FDA's approval, the ...

Novo Nordisk (NYSE:NVO) A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies, ...

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. The repeat offenders received their latest dressing-downs over a gathering of healthcare ...

Europe's largest pharmaceutical firm, Novo Nordisk, revealed positive trial results for its next-generation obesity drug, amycretin, marking a major step in its competition within the increasingly ...

A next-generation Novo Nordisk obesity drug designed to hit two targets has preliminary clinical data showing 22% weight loss, results that suggest the once-weekly injection could have an edge ...

Novo Nordisk shares rose sharply Friday after the ... the price of its drugs in the U.S. The company behind blockbuster obesity treatment Wegovy and diabetes drug Ozempic is busy developing ...